Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse
NCT05559788 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 34
Last updated 2022-09-29
Summary
This is a single-arm, prospective, non-interventional, real-world study to observe and evaluate the efficacy and safety of selinexor in combination with daratumumab and dexamethasone in patients with multiple myeloma at first relapse.
Conditions
- Multiple Myeloma at First Relapse
Sponsors & Collaborators
-
Fu chengcheng PhD
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-20
- Primary Completion
- 2024-06-01
- Completion
- 2025-06-01
More Related Trials
-
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
NCT04891744 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
NCT05201118 ·Status: UNKNOWN ·Phase: PHASE1
-
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
NCT06252792 ·Status: RECRUITING
-
Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
NCT05561049 ·Status: UNKNOWN
-
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT04925193 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
NCT00525447 ·Status: COMPLETED ·Phase: PHASE1
-
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT04661137 ·Status: SUSPENDED ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT05857982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
NCT01593410 ·Status: COMPLETED ·Phase: PHASE2
-
Selinexor Treatment of Refractory Myeloma
NCT02336815 ·Status: COMPLETED ·Phase: PHASE2
-
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
NCT03850704 ·Status: NO_LONGER_AVAILABLE
-
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT02985333 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02389543 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT05170789 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
NCT03809780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160 ·Status: COMPLETED ·Phase: PHASE3
-
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
NCT04941937 ·Status: RECRUITING ·Phase: PHASE2
-
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
NCT02348528 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07138209 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
NCT02158702 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
NCT02831686 ·Status: COMPLETED ·Phase: PHASE1
-
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
NCT03029234 ·Status: COMPLETED ·Phase: PHASE3